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This paper reports the effect of particle size within a resorbable composite on the in vivo degradation rate
and host response. Resorbable composites based on poly(D,L-lactide-co-glycolide) (PLGA) reinforced with
tricalcium phosphate (TCP) have shown suitable degradation, biological and mechanical properties for
bone repair. Composites with nano-sized TCP particles degrade more homogenously in vitro than equiv-
alent composites with micro-sized particles. In this study, PLGA and PLGA/TCP composites containing
micro- or nano-sized a-TCP particles were implanted into an ovine distal femoral condyle defect and
harvested at 6, 12, 18 and 24 weeks. An intimate interface was observed between the new bone tissue
and degrading implants. Visual scoring of histological images and semi-automated segmentation of
X-ray images were used to quantify implant degradation and the growth of new bone tissue in the
implant site. Bone growth into the implant site occurred at a similar rate for both composites and
the PLGA control. However, the in vivo degradation rate of the nanocomposite was slower than that of
the microcomposite and consequently more closely matched the rate of bone growth. For the first
6 weeks, the rate of in vivo degradation matched that of in vitro degradation, but lagged significantly
at longer time points. These results point to the potential use of ceramic particle size in controlling
composite degradation whilst maintaining good bone formation.
Statement of Significance
This paper concerns degradable composites for orthopaedic application. The effect of particle size on
implant degradation in vivo is not yet well characterised and these results give the first opportunity to
directly compare in vitro and in vivo degradation rates for composites with micro- and nano-sized parti-
cles. This type of data is vital for the validation of models of composite degradation behaviour, which will
lead to the design and manufacture of composites with a tailored, predictable degradation profile. The
trainable segmentation tool can be used for future studies where X-rays of partially degraded implants
(which have complicated greyscales and morphologies) need to be quantified without bias.
 2016 Acta Materialia Inc. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
1.1. PLGA/a-TCP composites
Composites based on poly(a-hydroxy) acids and calcium phos-
phates show promising degradation characteristics and mechani-
cal properties for use as an orthopaedic biomaterial [1–3]. Poly
(lactide-co-glycolide) is widely used in medicine as drug delivery
devices, suture anchors, screws and plates [4,5]. However, when
PLGA degrades acidic oligomers build up inside the sample and
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Calcium phosphates have been widely used in orthopaedic repair
for over 20 years [6]. Tricalcium phosphate (TCP) forms a direct
bond with bone and has been used successfully as a bone replace-
ment material [7,8]. Adding TCP to PLGA to form a composite
reduces the pH drop as TCP particles dissolve and buffer the acidic
degradation products [9]. There are several parameters that can be
altered in order to tailor the degradation profile of the composite
for a specific application. These include the characteristics of the
polymer matrix (e.g. crystallinity), the type of calcium phosphate
(e.g. a-TCP, b-TCP, hydroxyapatite (HA)), the composite processing
method and the weight fraction, size and shape of the calcium
phosphate reinforcement.
1.2. The effect of ceramic particle size in resorbable composites
As bone itself is a nanostructured composite, polymer matrix
composites with a nano-sized reinforcement phase (i.e. with
dimensions less than 1000 nm) have been investigated for use in
orthopaedic repair [10–13].
1.2.1. Mechanical properties
Reducing particle size in polymer based particulate composites
generally results in increased mechanical properties such as
stiffness and tensile strength [14]. However, due to their increased
surface area, nano-sized particles have a tendency to agglomerate
during composite preparation. This agglomeration can lead to con-
flicting results regarding the effect of particle size on composite
properties. The incorporation of nano-sized, rather than micro-
sized, HA and TCP particles dispersed in the matrix resulted in
higher 4-point bending strength and higher modulus of elasticity
in composites made of a polyamide fabric with a polysiloxane
matrix [15]. This was attributed to the better dispersion of the
nano-particles compared to micro-particles and their closer prox-
imity to the polyamide fibres. Conversely, the 3-point bending
strength and modulus of elasticity of poly(L-lactide)/HA and
PLGA/HA composites were higher with a HA particle size of 5 lm
than with a HA particle size of <200 nm [16]. This was attributed
to poor particle distribution in the composites with smaller
particles.
1.2.2. Degradation behaviour
The in vitro degradation behaviour of composites with nano-
sized particles has been shown to be more favourable than those
containing micro-sized particles. Freeze dried poly(lactide)/b-TCP
composites with nano-sized b-TCP particles were found to have a
stronger buffering effect in vitro than composites with micro-
sized b-TCP particles [9]. The in vitro degradation of PLGA/a-TCP
nanocomposites was found to be slower and more homogeneous
than that of microcomposites with the same ceramic loading
[17]. Significant mass loss for nanocomposites occurred after
43 days, compared with 36 days for microcomposites and 21 days
for PLGA control samples. The nanocomposites absorbed less water
(resulting in less swelling) and the degradation environment was
less acidic than with equivalent microcomposites. It is possible
that a-TCP may change phase to less soluble phases during the
hydrolytic degradation of the polymer degradation although an
XRD study of degrading PGA/a-TCP composites failed to find con-
clusive evidence for this [18].
1.2.3. Biological response
There is good evidence that adding nano-sized ceramic particles
to poly(a-hydroxy) acids improves the biological response of these
materials. The addition of nano-sized b-TCP enhanced the
osteoconductivity of freeze-dried poly(lactide)/b-TCP composite
scaffolds at 8 weeks in vivo although there was no difference inresponse at 2 and 4 weeks, implying that the difference in response
may not have been a function of the initial structure [9]. In vitro
cell culture of PLGA/a-TCP composites with human osteoblasts
showed improved cell attachment and spreading of osteoblast
cells, more rapid cell proliferation and a higher degree of osteoblast
differentiation on nanocomposites in comparison with equivalent
microcomposites [19]. In an in vivo study in a minipig model micro
and nanocomposites of bTCP with a high lactide to glycolide
polymer ratio showed greater push-out force than polymer only
at 8 weeks however minimal implant degradation was seen at this
time point [20].
The improved mechanical properties, degradation behaviour
and cell culture behaviour reported in the literature suggest that
nanocomposites have advantages over equivalent microcompos-
ites as orthopaedic implant materials. In this study, PLGA/a-TCP
composites were produced with micro- and nano-sized TCP
particles in order to investigate the effect of TCP size on the perfor-
mance of the composite in vivo. The choice of aTCP as a filler phase
allowed direct comparison with earlier in vitro studies [17].2. Methods
2.1. Material preparation
PLGA with a 50:50 M ratio of D,L-lactide to glycolide was pur-
chased (Lakeshore Biomaterials, Birmingham, Alabama, USA) with
a molecular weight of 65 kDa and an inherent viscosity of 0.47 dL/
g. a-TCP was synthesised in-house via an aqueous precipitation
reaction between 98% Ca(OH)2 and 85% ortho-H3PO4 at a molar
ratio of 3:2. The dried TCP cake was ground and calcined to obtain
the metastable a-TCP phase using the following furnace program:
heat at 2.5 C/min to 1400 C, dwell for 4 h at 1400 C and cool at
20 C/min to 20 C. After calcining, a solid lump of a-TCP was
obtained which was broken down to a powder using a pestle and
mortar. X-ray diffraction was used to identify the phase of the
calcined TCP. Semi-quantitative analysis of the spectra using High-
score Plus software (PANalytical, Almelo, Netherlands) showed
that the calcined TCP powder consisted of 100% a-TCP. Attenuated
total reflectance Fourier transform infrared spectroscopy (ATR-
FTIR) also confirmed that the TCP powder was the a-polymorph.
The Ca/P ratio of the calcined TCP powder determined with X-ray
fluorescence (XRF) spectroscopy was 1.53 ± 0.005, which is close
to the nominal Ca/P ratio of TCP of 1.50. Analytical reagent grade
acetone was used as the solvent for preparing the materials at a
solvent: polymer ratio of 5:1. Further acetone was added during
processing to compensate for solvent evaporation. The microcom-
posite material was produced by dispersing a-TCP powder in
acetone for approximately 10 min using a magnetic stirrer, adding
the PLGA pellets and stirring the mixture for a further 30 min. The
nanocomposite material was produced by attritor-milling (PE 075/
PR 01, Netzsch-Feinmahltechnik GmbH, Selb, Germany with attri-
tor agitator shaft and 2 mm diameter spherical alumina beads)
a-TCP powder in acetone for 2 h, gradually adding the PLGA pellets
and milling the mixture for a further 30 min. Both microcomposite
and nanocomposite materials contained 30 wt% a-TCP. The poly-
mer material was produced by attritor-milling PLGA in acetone
for 30 min without the addition of a-TCP. After mixing in acetone,
all materials were dried in air in PTFE containers with a height of
approximately 80 mm and a diameter of approximately 60 mm
for 2–4 days to evaporate the acetone. This was followed by further
drying in a vacuum oven at a temperature of 50 C and a vacuum
pressure of 800 mbar for approximately 4 days to remove any
residual acetone. The materials were then injection moulded using
a micro-injection moulder (DSM Research, Heerlen, Netherlands)
to produce cylindrical samples of length 12 mm and diameter
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implantation, sufficient for 6 replicates to be harvested at each of
4 time-points. All materials were sterilised by exposure to gamma
radiation (25 kGy absorbed dose, Isotron, Swindon, UK) prior to
implantation. Before fabrication, the polymer was stored in a
desiccator to avoid moisture capture. After fabrication, the sample
were dried in a vacuum oven at 50 C at 500 mbar. After removal
from the oven samples were stored in a desiccator or in polyethy-
lene containers under inert atmosphere. Although injection mould-
ing and irradiation may affect the molecular weight of the polymer,
all formulations were subjected to these processes so the relative
MWs are likely to have remained similar. We do not think that
the differences in processing required to produce micro- and
nano-composites are likely to have resulted in very different
molecular weights between the formulations. The number of repli-
cate samples per implant type per time point was determined on
the basis that significant differences in bone formation between
groups were seen in studies of bone graft substitute materials
using a similar implantation model [21] with the same number
of replicates per group.
2.2. Material characterisation
2.2.1. TCP particle size
Scanning electron microscopy (SEM) was used to characterise
the morphology of the composite materials and the dispersion
state of the a-TCP particles in the PLGA matrix. For microcompos-
ites, a low-vacuum W-filament SEM (JEOL JSM-5800LV) with an
accelerating voltage of 10 kV was used. 15 micrographs of the
microcomposite were obtained, from which at least 6000 particle
sizes were measured. In order to resolve the features of the
nanocomposites, a cold field emission electron gun (cFEG) SEM
(Hitachi S-5500) with an accelerating voltage of 2 kV was used.
Samples were frozen using liquid nitrogen and SEM specimens
were chipped off using a sharp razor blade and hammer.
Back-scattered electron mode was used to differentiate the a-TCP
particles (white) from the PLGA matrix (grey). Micrographs were
obtained from at least four different regions of each sample. At
least 20 micrographs of the nanocomposite were obtained, from
which at least 250 particle sizes were measured.
2.2.2. TCP weight fraction
Thermogravimetric analysis (TGA) (Q500 QA Instruments) was
used to determine the actual weight% of TCP in the composite sam-
ples and to confirm the removal of acetone. Nitrogen and air were
used as the balance gas and sample gas, respectively, for the TGA
experiments. A pre-weighed amount of material between 5 mg
and 15 mg was heated at a rate of 10 C/min from approximately
12 C to 600 C.
2.3. Animal model
An ovine model was chosen due to the similarities with humans
in weight, bone and joint structure and bone regeneration [21]. A
defect size of 12 mm deep and 6 mm in diameter was used to
accord with the size of the injection moulded implants. This is
sub-critical but was suitable for comparing the response of bone
to the different implant materials.
2.4. Surgical procedure
All procedures were carried out in accordance with the regula-
tions set out in the Animals (Scientific Procedures) Act 1986 and
were approved by the local animal study ethics committee. The
animals used were Welsh Mountain ewes aged between 2 and
5 years and weighed 30–50 kg. A total of thirty-six animals hadbilateral bone defects produced in the distal femoral condyle as
previously described [22,23]. Anaesthesia was induced with
Alfaxolone (Alfaxan) (3 mg/kg i.v.) and maintained using 2.5%
Isoflurane and 1.5% nitrous oxide. Depocillin (50 mg/kg i.m.) and
Carprofen (Rimidyl) (1.5 mg/kg s.c.) were given peri-operatively
to produce antibiotic and analgesic cover respectively. The skin
over both hind limbs was shaved and scrubbed for sterile surgery.
An incision was made over the lateral femoral condyle and the sur-
face of the condyle exposed. The defect was drilled using a 6 mm
diameter drill bit with a drill stop collar set at 12 mm. The defect
was rinsed with sterile saline and the implant inserted in a ‘press
fit’ manner. Nine animals were randomly assigned to each of four
groups for implantation times of 6, 12, 18 and 24 weeks and within
each group the polymer only, microcomposite and nanocomposite
materials were randomly assigned to each defect site. Subcuta-
neous tissue and skin were closed routinely and the animals
allowed to recover quietly. On recovery the animals were allowed
full weight-bearing. Carprofen (1.5 mg/kg) was given eighteen
hours after surgery and Depocillin (50 mg/kg) on post-operative
days 1 and 2. The fluorochrome labels calcein (15 mg/kg) and ali-
zarin red (40 mg/kg) were given by intravenous injection into the
cephalic vein 14 and 7 days respectively prior to sacrifice. At the
appropriate time points; weeks 6, 12, 18 and 24, the animals were
killed by an overdose of intravenous pentobarbitone. The femoral
heads were removed en-bloc and placed in fresh, ice cold 4% w/v
paraformaldehyde. After fixation the femoral heads were rinsed
in saline and l-CT carried out. The l-CT images were used to
orientate the bone for sectioning.
2.5. Implant embedding and sectioning
Initial cuts were made around the implant site to remove extra-
neous bone and the remaining bone containing the implant was
dehydrated by sequential transfer through 40%, 70%, 90% and
100% v/v alcohol; each solution being changed twice over a period
of twenty-four hours. Following a further change of 100% alcohol,
the samples were defatted in acetone and then infiltrated in
methylmethacrylate resin over a period of one week, with the resin
being changed on one occasion. Fresh resin containing 2.5% v/v
dibutylphthalate and 2.5% w/v benzoyl peroxide was added to
the specimens and the resin allowed to polymerise in glass jars.
Cutting of the resin blocks containing the implants and surround-
ing bone was carried out using an Accutom 5 rotating saw (Struers)
with a diamond impregnated blade. The resin blocks were
removed from the jars, cut to a manageable size and cut through
the centre of the longitudinal axis of the implant site using the
lCT images as a guide. Sections were cut parallel to this central
cut for staining and analysis. Sections were ground flat and pol-
ished using diamond impregnated pads and diamond paste respec-
tively on a Rotopol 21 polisher (Struers). The sections were glued
to Perspex slides (70  40  2 mm) using cyanoacrylate glue.
2.6. Staining
Sections were surface-stained with 0.25% w/v toluidine blue
(pH 9) at 56 C for 30 min in order to observe the presence of
osteoid, and the distribution and organisation of cells within the
tissue. The staining also allowed residual composite material to
be seen.
2.7. Histology and visual scoring
Stained sections were examined using a light microscope (Leitz
Dialux 20, Leica, UK). The presence of inflammatory mononuclear
cells, osteoclasts and evidence of bone resorption was recorded.
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and Surveyor software (Objective Imaging, UK).
The percentages of bone and implant in the implant site were
estimated by examining the stained sections under the microscope
using a low power (1) objective providing a score for each sec-
tion. The area of trabecular bone tissue was scored between 0
and 50% of the area assessed in increments of 10% and the area
of residual implant was scored from 100% to 0% of the area
assessed again with increments of 10%. Confirmation of the iden-
tity of the bone or implant material during scoring was done using
a 10 objective as required. Scoring was done by one observer who
was not aware of the time of harvest or the implant material in
each section.
2.8. X-ray scoring
2.8.1. X-ray image acquisition and preparation
X-ray images of 72 cross-sections were taken using a Kubtec
Xpert 80 and Digicom 4.0 software, with an X-ray source voltage
of 30 kV and current of 800 lA. Samples were placed in the same
position in the X-ray chamber to minimise any variations in image
intensity due to the X-ray source. X-ray images were analysed
using Fiji [24], an image processing package based on ImageJ.
The images were scaled and a rectangle of size 5.5 mm  11.5 mm
positioned over each implant site and cropped. The brightness and
contrast of the images were equalised using the automatic settings
in Fiji.
2.8.2. X-ray image segmentation
The implant sites in this study were categorised into four dis-
tinct groups: those which contained no bone or implant (not
shown), those which contained bone only (see Fig. 1a), those which
contained implant only (see Fig. 1b) and those which contained
both bone and implant (see Fig. 1c). A trainable image segmenta-
tion plugin [25] was used to segment the images and quantify
the areas of bone and implant present. These values were
expressed as a percentage of the area assessed. The plugin was
trained for one image in each group and then applied to the
remainder of the images in the group. This method ensures that
the regions are being segmented correctly, as the user has trained
the program to identify the different pixel intensities, but the seg-
mentation process is automated which removes any bias from the
user. The user was not aware of the time of harvest or the implant
material for any of the images.Fig. 1. Example X-ray images (left) and their corresponding segmented images (right
(nanocomposite 12 weeks) and c) bone and implant (nanocomposite 24 weeks). In the s
5.5 mm  11.5 mm. (For interpretation of the references to colour in this figure legend,2.9. Statistics
%Bone and %Implant data from visual scoring and X-ray seg-
mentation were analysed using SPSS Statistics 20 (IBM, USA).
Non-parametric statistical tests were used, which make no
assumptions about the probability distributions of the data. The
Kruskal-Wallis test was used to compare the data at each time-
point and when significance was seen (p < 0.05), pairwise compar-
isons were carried out using the Mann-Whitney U test.3. Results
3.1. Material characterisation
Fig. 2 shows example micrographs for the micro- and nanocom-
posite materials.
Fig. 3 shows particle number histograms for the microcompos-
ite and nanocomposite materials.
TGA showed that the actual weight% of TCP in both microcom-
posites and nanocomposites was relatively close to 30 wt% (see
Table 1).3.2. Bone ingrowth and implant degradation
Two different independent methods were used to analyse bone
ingrowth and implant degradation: visual scoring from histological
images and segmentation of X-ray images. The data from these
methods are very similar, which confirms that the data is represen-
tative of the material differences.
Figs. 4 and 5 show %Bone and %Implant data respectively, as
determined by visual scoring and X-ray segmentation as a function
of degradation time. Due to the nature of biological data, there was
sometimes a large spread in the values for each time point. Both
methods show similar trends for both bone ingrowth and implant
degradation.3.3. Statistics
Using non-parametric statistics (no assumptions about normal-
ity and variance) to analyse the visual scoring and X-ray segmen-
tation %Bone data the Kruskal-Wallis test (more than 2 groups, in
this case 3) showed there was no difference between the amount
of bone as a function of implant type at any time point.) for implant sites containing a) bone only (polymer 24 weeks) b) implant only
egmented images, black = background, white = bone, blue = implant. All images are
the reader is referred to the web version of this article.)
Fig. 2. Back-scattered scanning electron micrographs for the a) microcomposite and b) nanocomposite implant materials.
Fig. 4. Bar charts showing mean %Bone area as determined by a) visual scoring and
b) X-ray segmentation. Error bars are standard deviations of the mean.
Fig. 3. Particle number histograms for the microcomposite (white) and nanocom-
posite (grey) implant materials.
Table 1
Weight percentages of TCP in micro- and nanocomposite samples as determined by
TGA.
Sample wt% a-TCP determined by TGA
Microcomposite 31.2
Nanocomposite 27.8
344 S.M. Bennett et al. / Acta Biomaterialia 45 (2016) 340–348The X-ray segmentation %Implant data showed there were sig-
nificant differences between the amount of remaining implant as a
function of implant type at 12, 18 and 24 weeks (p < 0.05 in each
case). This is primarily due to the absence of residual implant in
the polymer samples. The Mann Whitney U test showed a signifi-
cant difference between the micro- and nanocomposite (0.026) at
12 weeks but not at 24 weeks (0.18). Although the visual scoring
showed a very similar time course for bone formation and loss of
implant within the implant site to that seen with X-ray segmenta-
tion (see Fig. 5), comparison of the scores for the 3 materials at
each time point did not reach statistical significance.
3.4. Histology
Fig. 6 shows mosaic histological images of cross-sections of the
implant sites for a 6 week polymer, 24 week microcomposite and
24 week nanocomposite sample.The majority of implant sites were surrounded by trabecular
bone, however some were inserted adjacent to the marrow cavity
(see Fig. 6a). There was very little implant left in any of the
polymer implant sites, even at the earliest time-point. Fig. 6a
shows an implant site for a 6 week polymer sample which is full
of granulation tissue and contains a small amount of polymer
Fig. 5. Bar charts showing mean %Implant area as determined by a) visual scoring
and b) X-ray segmentation. Error bars are standard deviations of the mean. There is
no %Implant area data for polymer samples measured by X-ray segmentation as
polymer is radio-tra.
S.M. Bennett et al. / Acta Biomaterialia 45 (2016) 340–348 345(<10%) but no new bone tissue. Compared with the polymer
implants, microcomposite and nanocomposite implants were
slower to degrade. There was generally more residual nanocom-
posite implant than microcomposite implant for a given time-
point. Fig. 6b and c show a microcomposite and nanocomposite
implant site respectively at 24 weeks degradation. There is more
residual implant (stained grey/black) in the nanocomposite sample
than the microcomposite sample and both implant sites contain
new bone tissue surrounded by granulation tissue. Fig. 7a–c shows
magnified areas of sections taken with an optical microscope.
No large aggregates of mononuclear cells indicating a gross
inflammatory or immunological response were observed in any
samples. An intimate interface was seen between new bone tissue
and degrading microcomposite and nanocomposite implants (see
Fig. 7a), which was not seen in polymer samples. Large multi-
nucleated cells resorbing bone were observed in all materials at
the earliest time-point only (see Fig. 7b). Multi-nucleate cells were
also seen resorbing the composite implant materials. Fig. 7c shows
a large multi-nucleated cell resorbing a nanocomposite implant.
Fig. 7d shows continuing bone formation in a nanocomposite
implant site between 22 and 23 weeks, evidenced by the separa-
tion of the two fluorochrome labels.4. Discussion
4.1. Effect of TCP on PLGA degradation
In this work the addition of a-TCP to PLGA slowed the in vivo
degradation significantly (see Fig. 5b). The results of this study
were compared with previous work on equivalent materials in
order to determine whether rates of degradation in vitro corre-
sponded to those seen in vivo. Fig. 8 shows residual %Implant data
from visual scoring and X-ray scoring from this in vivo study and %
Implant remaining data from an in vitro study with equivalent
materials [17]. In the experiment reported all samples were
degraded in 0.01 M PBS solution at 37 C without agitation. A sam-
ple mass to PBS volume ratio of 6 mg/mL was used for both com-
posite and PLGA samples. PBS solutions were unchanged during
the whole period of degradation. pH changes in the degradation
experiment are reported in [17]. Note: the in vitro experiment is
shorter than the in vivo experiment.
The graphs in Fig. 8 show that at around 6 weeks (42 days) of
degradation, the amount of implant remaining was similar for
in vitro and in vivo data (around 10% for PLGA, 65% for microcom-
posite and around 80% for nanocomposite). However, the degrada-
tion of composites proceeds more rapidly in vitro after 6 weeks
compared to in vivo. One reason for this could be the differing
pH environments between the studies. In vitro, the buffering effect
of PBS (phosphate-buffered saline) is overwhelmed after about
45 days and the pH of the degradation media drops to below 4
by 85 days [17]. Both the rate of hydrolysis of PLGA and the solu-
bility of TCP increase at lower pH, increasing the rate of sample
degradation. In contrast, in vivo the acidic degradation by-
products can be removed from the vicinity of the implant site
and so acidic catalysis of implant degradation is reduced. Enzymes
(present in vivo but not in vitro) can accelerate the degradation of
resorbable polymers, however the published data on the role of
enzymes on PLGA degradation is unclear [26–28]. The fact that
physiological pH is likely to be maintained in the in vivo study,
but not the in vitro study, is likely to be a significant factor in the
difference in degradation rates between the studies.4.2. Effect of TCP particle size
The results of this study show that modifying the particle size
alters the in vivo degradation properties of PLGA/TCP composites
(p = 0.026 at 12 weeks between microcomposite and nanocompos-
ite). Both visual and X-ray scoring show that the nanocomposite
degraded at a slower rate than the microcomposite. This effect
was also observed previously in vitro [17], where the difference
was attributed to more effective buffering from the nano-sized
TCP particles. An intimate association was seen between the tissue
and both the microcomposite and the nanocomposite implants
reflecting the biocompatible nature of these materials in osseous
tissue.4.3. Clinical relevance
Nanocomposite implants degraded more slowly than micro-
composite implants (see Fig. 5). Cellular breakdown of the implant
was observed in nanocomposite implants (see Fig. 7) and fluores-
cent labelling indicated that bone forming cells were still active
between 22 and 23 weeks (Fig. 7d). Therefore the nanocomposite
implant shows potential for use in humans, where a relatively slow
degradation rate with intimate bone ingrowth and good biological
activity in the implant site is desirable. If implant degradation is
too fast compared to the rate of bone growth then a hole could
be left in the bone, as seen with the pure PLGA implant (see
Fig. 7. Histological sections (toluidine blue staining) showing a) intimate interface between bone and implant (indicated by arrows) in 24 week nanocomposite sample, b)
large multi-nucleated cells (indicated by arrows) resorbing bone in a 6 week nanocomposite sample, c) a large multi-nucleated cell (arrowed) resorbing implant in a 24 week
nanocomposite sample and d) calcein green and alizarin red fluorochrome labels (arrowed) showing new bone formation in a 24 week nanocomposite sample. (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 6. Histological sections (toluidine blue staining) showing implant sites for a) polymer 6 weeks, b) microcomposite 24 weeks and c) nanocomposite 24 weeks. Residual
implant is indicated by asterisks and arrows point to new bone. Scale bars are 2 mm. (For interpretation of the references to colour in this figure legend, the reader is referred
to the web version of this article.)
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Fig. 8. Graphs comparing in vitro degradation data from published values in the literature [17] (crosses) with in vivo data from visual scoring (filled squares) and X-ray
segmentation (unfilled squares) from this study for a) PLGA, b) microcomposite and c) nanocomposite. Values are means ± s.d. n = 3 in vitro; n = 6 in vivo.
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size defect. The composite degradation rate was affected by parti-
cle size, indicating that this variable could be used to produce
implants with tailored degradation profiles. Bone resorption
(osteoclast activity) is a concern; however, it was only seen at
the early time-point (6 weeks) and was seen in around all
materials.
5. Conclusions
 A semi-automated segmentation method was used to identify
bone and implant in X-rays of implant sites. The method gave
very similar results to those obtained by histological examina-
tion, so it could be used as a quick and easy method of quanti-
fying degradation in the laboratory. However it is limited to
radio-opaque materials and tissues.
 The implant degradation seen in vivo correlates well with data
from in vitro studies of similar materials for the first 6 weeks
of degradation. After 6 weeks the in vivo and in vitro degrada-
tion rates differ (probably due to differing local pH environ-
ments) but the ranking of the rates is consistent.
 Bone growth into the implant site occurred at a similar rate
for polymer, microcomposite and nanocomposite implants
in vivo over 24 weeks. However, the nanocomposite implants
degraded more slowly than microcomposite implants. The
nanocomposite may therefore be more appropriate for ortho-paedic implants in human patients where the rate of bone
ingrowth (30% new bone coverage at 24 weeks) is more clo-
sely matched by the slower degradation of the nano-
composite (60–75% lost at 24 weeks) than the micro-
composite (90–95% lost at 24 weeks). An intimate interface
was seen between the new bone tissue and the degrading
implants for both the microcomposite and nanocomposite
materials.
 Osteoclast activity resorbing bone was observed around all
implant materials, but only at the earliest time-point (6 weeks).
Multinucleate cells were seen at later time points but were con-
fined to resorbing the implant material.
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